Bilici, A. Et Al. 2022. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).. JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16 .

Bilici, A., Olmez, O. F., Sezer, A., Oksuzoglu, B., Kaplan, M. A., Karadurmus, N., ... Cubukcu, E.(2022). Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).. JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16.

Bilici, Ahmet Et Al. "Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).," JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16, 2022

Bilici, Ahmet Et Al. "Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).." JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16, 2022

Bilici, A. Et Al. (2022) . "Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).." JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16.

@article{article, author={Ahmet Bilici Et Al. }, title={Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2022}